Out-of-pocket cost burden in pediatric inflammatory bowel disease: A cross-sectional cohort analysis

Inflammatory Bowel Diseases

Volumn 21, Issue 6, 2015, Pages 1368-1377

  Sin, Aaron T ^a   Damman, Jennifer L ^b   Ziring, David A ^c   Gleghorn, Elizabeth E ^b   Garcia Careaga, Manuel G ^d,e   Gugig, Roberto R ^f   Hunter, Anna K ^f   Burgis, Jennifer C ^e,g   Bass, Dorsey M ^e   Park, K T ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

^f CHILDREN S HOSPITAL CENTRAL CALIFORNIA   (United States)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Costs; Crohn's disease; cross sectional analysis; health care; inflammatory bowel disease; out of pocket; pediatric; Qualtrics; ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE;

ARTICLE; CHILD; COHORT ANALYSIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; EMERGENCY WARD; FAMILY SIZE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HOSPITALIZATION; HOUSEHOLD; HUMAN; INCOME; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; OUTPATIENT; PARENT; PHYSICIAN; PRIORITY JOURNAL; PROBABILITY; SOCIAL MEDIA; ULCERATIVE COLITIS; ADOLESCENT; AMBULATORY CARE; CALIFORNIA; COST OF ILLNESS; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE SURVEY; HOSPITAL EMERGENCY SERVICE; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CALIFORNIA; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; COST OF ILLNESS; CROHN DISEASE; CROSS-SECTIONAL STUDIES; EMERGENCY SERVICE, HOSPITAL; FINANCING, PERSONAL; HEALTH CARE SURVEYS; HOSPITALIZATION; HUMANS; OFFICE VISITS; PARENTS; SOCIOECONOMIC FACTORS;

EID: 84929889647     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000374     Document Type: Article

References (33)

1. Biank V, Broeckel U, Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis. 2007;13:1430-1438.
2. Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am. 2009;38:611-628.
3. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113.
4. Park KT, Bass D. Inflammatory bowel disease-attributable costs and costeffective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603-1609.
5. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
6. Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics. 2011;29:387-401.
7. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut. 2014;63:72-79.
8. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53:1471-1478.
9. Blumenstein I, Bock H, Weber C, et al. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm Bowel Dis. 2008;14:53-60.
10. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med. 2008;50:1261-1272.
11. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728.
12. Smith M, Saunders R, Stuckhardt L, et al. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Committee on the Learning Health Care System in America, Institute of Medicine. Washington, DC: National Academies Press; 2013.
13. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18:509-523.
14. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122.
15. Rohde F. STATISTICAL BRIEF #413: Prescription drug expenditures in the 10 Largest states, 2010. Med Expend Panel Surv. 2013.
16. Poverty Guidelines. Center for Medicaid and Children's Health Insurance Program [CHIP] Services, Centers for Medicare and Medicaid Services, 2014.
17. Medi-cal Application Guidelines. Santa Clara, County: Santa Clara Dept of Public Health; 2014.
18. Rural Health Research Center. Rural Urban Commuting Area (RUCA) Codes Data. Seattle, WA; 2005. Available at: http://depts.washington. edu/uwruca/ruca-data.php. Accessed September 18, 2014.
19. U.S. Census Bureau. American Community Survey: California. Washington, DC; 2012. Available at: http://www.dof.ca.gov/research/demographic/state-census-data-center/american-community-survey/. Accessed September 18, 2014.
20. Bernard DM, Johansson P, Fang Z. Out-of-pocket healthcare expenditure burdens among nonelderly adults with hypertension. Am J Manag Care. 2014;20:406-413.
21. Blumenthal D, Stremikis K, Cutler D. Health care spending-a giant slain or sleeping? N Engl J Med. 2013;369:2551-2557.
22. Schoen C, Osborn R, Squires D, et al. Access, affordability, and insurance complexity are often worse in the United States compared to ten other countries. Health Aff (Millwood). 2013;32:2205-2215.
23. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319-328.
24. Stark R, Konig H-H, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24:797-814.
25. Prenzler A, Bokemeyer B, Vonder Schulenburg J-M, et al. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011;12:273-283.
26. Longobardi T. Work losses related to inflammatory bowel disease in the United States results from the National Health Interview Survey. Am J Gastroenterol. 2003;98:1064-1072.
27. Gunnarsson C, Chen J, Rizzo JA, et al. The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data. J Occup Environ Med. 2013;55:393-401.
28. Park KT, Sin A, Wu M, et al. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience. Inflamm Bowel Dis. 2014;20:1242-1249.
29. Bernstein CN, Loftus EV, Ng SC, et al. Hospitalisations and surgery in Crohn's disease. Gut. 2012;61:622-629.
30. Cannom RR, Kaiser AM, Ault GT, et al. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. 2009;75:976-980.
31. Soon IS, Wrobel I, deBruyn JC, et al. Postoperative complications following colectomy for ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2012;54:763-768.
32. Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis. 2012;18:1641-1646.
33. Park M, Bhattacharya J, Park K. Healthcare expenditures in inflammatory bowel disease by insurance. Status, income, and clinical care setting in a nationally representative sample. Peer J. 2014;2:e587.